Analysts at William Blair initiated coverage on shares of Neuronetics (NASDAQ:STIM – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set an “outperform” rating on the stock.
Several other equities analysts have also recently commented on the stock. Citigroup restated a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a report on Monday, September 14th. BTIG Research reiterated a “buy” rating and set a $6.00 price target on shares of Neuronetics in a research report on Thursday, September 17th. Finally, B. Riley Financial lifted their price objective on shares of Neuronetics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.
Check Out Our Latest Stock Report on STIM
Neuronetics Stock Up 2.4%
Neuronetics (NASDAQ:STIM – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.07. The business had revenue of $41.96 million during the quarter, compared to analysts’ expectations of $40.42 million. Neuronetics had a negative net margin of 14.45% and a negative return on equity of 102.23%. Sell-side analysts anticipate that Neuronetics will post -0.30 EPS for the current fiscal year.
Insider Activity at Neuronetics
In related news, major shareholder Jorey Chernett sold 2,187,051 shares of the company’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $1.15, for a total transaction of $2,515,108.65. Following the completion of the sale, the insider directly owned 7,325,577 shares in the company, valued at $8,424,413.55. This represents a 22.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 3,335,411 shares of company stock worth $4,479,146. 8.40% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP boosted its stake in shares of Neuronetics by 26,974.6% in the 3rd quarter. Allworth Financial LP now owns 45,756 shares of the company’s stock valued at $107,000 after purchasing an additional 45,587 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Neuronetics during the 3rd quarter valued at approximately $69,000. Marshall Wace LLP increased its position in Neuronetics by 219.5% during the 3rd quarter. Marshall Wace LLP now owns 1,551,840 shares of the company’s stock worth $3,631,000 after purchasing an additional 1,066,148 shares in the last quarter. Empowered Funds LLC acquired a new position in Neuronetics during the 3rd quarter worth approximately $211,000. Finally, HighTower Advisors LLC increased its position in Neuronetics by 95.4% during the 3rd quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company’s stock worth $2,578,000 after purchasing an additional 537,761 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.
Recommended Stories
- Five stocks we like better than Neuronetics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
